1. Home
  2. ANL

as of 11-13-2026 3:19pm EST

$10.80
+$0.19
+1.79%
Stocks Nasdaq

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Founded: 2004 Country:
Singapore
Singapore
Employees: N/A City: N/A
Market Cap: 998.8M IPO Year: 2022
Target Price: $29.50 AVG Volume (30 days): 268.1K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.88 - $17.25 Next Earning Date: 08-14-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 243.83% Revenue Growth (next year): -55.54%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Adlai Nortye Ltd. (ANL)

Ji Ping

Director

Sell
ANL Sep 30, 2026

Avg Cost/Share

$15.99

Shares

10,000

Total Value

$159,900.00

Owned After

126,453

Ji Ping

Director

Sell
ANL Sep 29, 2026

Avg Cost/Share

$15.77

Shares

214

Total Value

$3,374.78

Owned After

126,453

SEC Form 4

Sell
ANL Aug 26, 2026

Avg Cost/Share

$14.25

Shares

5,667

Total Value

$80,754.75

Owned After

147,757

SEC Form 4

Sell
ANL Aug 24, 2026

Avg Cost/Share

$13.98

Shares

6,000

Total Value

$83,880.00

Owned After

147,757

SEC Form 4

Share on Social Networks: